Pharmaceutical Preparations · DE · CIK 2036042
Sionna Therapeutics develops novel medicines to normalize CFTR protein function for cystic fibrosis patients
Comparable business profile · signals at a glance
In the 90 days to Mar 5, 2026: 4 sold $16.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 5, 2026 | Fitzpatrick JenniferChief Legal Officer | Sell | 10,250 | $33.86 | $347K |
| Feb 3, 2026 | Orbimed Capital Gp Viii LlcDirector | Sell | 29,063 | $44.58 | $1.3M |
| Feb 3, 2026 | Thompson Peter A.Director | Sell | 29,063 | $44.58 | $1.3M |
| Feb 2, 2026 | Thompson Peter A.Director | Sell | 1,890 | $44.57 | $84K |
| Feb 2, 2026 | Orbimed Capital Gp Viii LlcDirector | Sell | 1,890 | $44.57 | $84K |
| Jan 22, 2026 | Winkelried JonTenPercentOwner | Sell | 250,000 | $40.00 | $10.0M |
| Dec 24, 2025 | Orbimed Capital Gp Viii LlcDirector | Sell | 33,356 | $44.55 | $1.5M |
| Dec 24, 2025 | Thompson Peter A.Director | Sell | 33,356 | $44.55 | $1.5M |
| Dec 19, 2025 | Thompson Peter A.Director | Sell | 875 | $44.49 | $39K |
| Dec 19, 2025 | Orbimed Capital Gp Viii LlcDirector | Sell | 875 | $44.49 | $39K |
| Dec 18, 2025 | Thompson Peter A.Director | Sell | 100 | $44.49 | $4K |
| Dec 18, 2025 | Orbimed Capital Gp Viii LlcDirector | Sell | 100 | $44.49 | $4K |
| Dec 17, 2025 | Thompson Peter A.Director | Sell | 900 | $44.50 | $40K |
| Dec 17, 2025 | Orbimed Capital Gp Viii LlcDirector | Sell | 900 | $44.50 | $40K |
| Dec 5, 2025 | Fitzpatrick JenniferChief Legal Officer | Sell | 10,250 | $40.52 | $415K |
| Nov 26, 2025 | Thompson Peter A.Director | Sell | 1,600 | $44.49 | $71K |
| Nov 26, 2025 | Orbimed Advisors LlcDirector | Sell | 1,600 | $44.49 | $71K |
| Nov 25, 2025 | Thompson Peter A.Director | Sell | 11,890 | $44.60 | $530K |
| Nov 25, 2025 | Orbimed Advisors LlcDirector | Sell | 11,890 | $44.60 | $530K |
| Nov 24, 2025 | Orbimed Advisors LlcDirector | Sell | 94,583 | $44.54 | $4.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.